



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 705.

Corp. Office: "Strides House", Billekahalli, Bannerghatta Road, Bangalore-560 076.

**UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED MARCH 31, 2009**

Rs.in Lakhs

Sl. No.	Particulars	UNAUDITED		AUDITED
		3 Months ended 31.03.2009	3 Months ended 31.03.2008	12 Months ended 31.12.2008
1	(a) Net Sales / Income from Operations	16,975.82	11,968.76	59,313.75
	(b) Other Operating Income	1,626.30	900.99	6,877.32
	Total Income	18,602.12	12,869.75	66,191.07
2	Expenditure			
	(a) (Increase) / decrease in stock in trade and work in progress	(1,090.80)	89.68	(442.40)
	(b) Consumption of materials	9,799.95	5,934.27	30,844.20
	(c) Purchase of traded goods	684.76	1,048.36	3,804.32
	(d) Employee cost	1,542.42	1,269.11	6,314.51
	(e) Depreciation	449.62	493.59	1,887.67
	(f) Other Expenditure	2,768.00	2,298.48	12,155.31
	Total Expenditure	14,153.95	11,133.49	54,563.61
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	4,448.17	1,736.26	11,627.46
4	Other Income	-	-	22.12
5	Profit before Interest & Exceptional Items (3+4)	4,448.17	1,736.26	11,649.58
6	Interest	1,570.00	1,351.65	6,542.73
7	Profit after Interest but before Exceptional Items (5-6)	2,878.17	384.61	5,106.85
8	Exceptional Items:			
	- Exchange Fluctuation loss (Net)	3,845.62	1,980.38	18,419.36
	- Exchange gains on restatement of Hedged investments	(2,041.24)	-	(9,234.02)
	- Changes in fair value of Options embedded in FCCBs	(1,089.35)	-	(4,522.15)
9	Profit / (Loss) from Ordinary Activities before tax (7- 8)	2,163.14	(1,595.77)	443.66
10	Provision for Taxation - Current tax	245.00	-	140.00
	- Deferred tax	-	-	(210.00)
	- Fringe benefit tax	15.00	9.00	40.20
	- MAT Credit entitlement	(245.00)	-	(140.00)
11	Net Profit / (Loss) from Ordinary activities after tax (9-10)	2,148.14	(1,604.77)	613.46
12	Extraordinary Item	-	-	-
13	Net Profit / (Loss) for the period	2,148.14	(1,604.77)	613.46
14	Paid-up Equity Share Capital (Face value of Rs.10/-each)	4,005.00	3,900.43	4,005.00
15	Reserves excluding revaluation reserves	-	-	28,973.30
16	Earnings per Share (EPS) :			
	Basic & Diluted EPS after Extraordinary items for the year (Rs.)			
	(a) Basic EPS	5.15	(4.69)	0.69
	(b) Diluted EPS	5.07	(4.69)	0.69
17	Aggregate of Public shareholding :			
	(a) Number of shares	29,707,086	30,916,911	29,707,086
	(b) Percentage of shareholding	74.17%	79.27%	74.17%
18	Promoters and Promoter group shareholding :			
	(a) Pledged / Encumbered			
	- Number of shares	6,896,000	-	-
	- Percentage of shareholding	17.22%	-	-
	(b) Non Pledged / Encumbered			
	- Number of shares	3,446,928	-	-
	- Percentage of shareholding	8.61%	-	-

Notes :

- The above standalone results of the Company were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on April 24, 2009.
- The Statutory Auditors have carried out a limited review of the standalone results.
- During the quarter ended March 31, 2009, Pharmasave Australia Pty Ltd, Australia became a subsidiary of the Company, consequent to acquisition made by Ascent Pharmahealth Limited, Australia, a subsidiary of Linkace Limited, Cyprus, a wholly owned subsidiary of the Company.
- On April 13, 2009, the Board of Directors of the Company, subject to corporate, regulatory, statutory and other approvals, granted approval for reorganisation of the Company's business into 3 separate entities; i) Speciality Pharmaceuticals, ii) Pharmaceuticals and iii) Research and Development with effect from January 1, 2009.
- The Company has granted 300,000 options under the Strides Arcolab ESOP-2008 (Director) at Rs. 59.00 per option (exercise price) to few Directors of the Company and 100,000 options under the Strides Arcolab ESOP-2008 at Rs. 59.00 per option (exercise price) to an eligible employee of the Company.
- The Company early adopted Accounting Standard-30 *Financial Instrument: Recognition and Measurement* during the year ended December 31, 2008. Consequently, the net profits for the year ended December 31, 2008 includes Rs.12,606.80 Lakhs on adjustment made in pursuance of the said Standard.
- Exchange fluctuation loss (net) is on account of restatement of foreign currency convertible bonds, External Commercial Borrowings and losses on forward exchange contracts net of exchange losses attributed to loans that have been designated as hedging instruments against Net Investments in foreign operation.
- The Company operates exclusively in the Pharmaceuticals business segment and as such there is no reportable segment information as per Accounting Standard 17.
- Investor grievances received and disposed off during the quarter ended March 31, 2009 :
a) Pending complaints at the beginning of the quarter – Nil b) No. of Complaints received - 13
c) Complaints disposed - 13 d) Complaints unresolved - Nil
- Previous period figures have been recast / restated wherever necessary to conform to the current period's classification.

For and on behalf of Board

**Arun Kumar
Vice Chairman & Managing Director**

Mumbai, April 24, 2009